(R)-2-氨基-3-羟基-3-甲基丁酸 | 2280-48-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 缬氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (R)-2-氨基-3-羟基-3-甲基丁酸
• 中文别名: D-BATE-羟基缬氨酸,(R)-2-氨基-3-羟基-3-甲基丁酸；D-BETA-羟基缬氨酸；D-beta-羟基缬氨酸；D-BATE-羟基缬氨酸
• 英文名称: (R)-β-hydroxy-valine
• 英文别名: (2R)-2-azaniumyl-3-hydroxy-3-methylbutanoate
• CAS: 2280-48-0
• 化学式: C₅H₁₁NO₃
• 分子量: 133.147
• InChiKey: LDRFQSZFVGJGGP-VKHMYHEASA-N

物化性质

• 沸点：
  245.66°C (rough estimate)
• 密度：
  1.2510 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2922509090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	(R)-(-)-2-Amino-3-hydroxy-3-methylbutanoic acid Material Safety Data Sheet
Synonym:	3-Hydroxy-D-valine
CAS:	2280-48-0

Section 1 - Chemical Product MSDS Name:(R)-(-)-2-Amino-3-hydroxy-3-methylbutanoic acid Material Safety Data Sheet
Synonym:3-Hydroxy-D-valine

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2280-48-0	3-Hydroxy-D-valine	99	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Avoid breathing dust.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2280-48-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H11NO3
Molecular Weight: 133.15

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2280-48-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Hydroxy-D-valine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 2280-48-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2280-48-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2280-48-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (R)-2-氨基-3-羟基-3-甲基丁酸 在 碘 、 potassium carbonate 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 18.5h， 生成 (R)-4-(1-(5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxy-2-methylpropylamino)-3-methyl-2-(trifluoromethyl)benzonitrile
  参考文献：
  名称：

  Selective Androgen Receptor Modulators

  摘要：

  该发明提供了如本文所述的化合物或其药用可接受的盐，包括一种如本文所述的化合物或其药用可接受的盐和药用可接受的赋形剂的制药组合物，使用如本文所述的化合物或组合物调节雄激素受体的方法，使用如本文所述的化合物和组合物治疗通过雄激素受体调节剂有益治疗的疾病的方法（例如，肌少症、前列腺癌、避孕、与2型糖尿病相关的疾病或疾病、贫血、抑郁症和肾病），以及制备如本文所述的化合物和制备相同的有用中间体的方法。

  公开号：

  US20120004270A1
• 作为产物：
  描述：

  3,3-二甲基丙烯酸 在 palladium on activated charcoal ruthenium trichloride 、 sodium periodate 、 氯化亚砜 、 sodium azide 、 AD-mix-β 、 氢气 、 氢气 、 caesium carbonate 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 (R)-2-氨基-3-羟基-3-甲基丁酸
  参考文献：
  名称：

  An Enantiomeric Synthesis of allo-Threonines and β-Hydroxyvalines

  摘要：

  DOI：

  10.1021/jo960141c

文献信息

• Enantioselective synthesis of non-proteinogenic amino acids via metallated bis-lactim ethers of 2,5-diketopiperazines
  作者：Ulrich Schöllkopf

  DOI：10.1016/s0040-4020(01)91926-x

  日期：1983.1

  excess = asymmetric induction) of the adduct exceeds 95%. On hydrolysis the adducts are cleaved liberating the chiral auxiliary (used to build up the bis-lactim ether 1) and the target molecules, the optically active amino acid methyl esters of type 8,19,25 or 36. The two amino acid esters are separable either by fractional distillation or (eventually after further hydrolysis to amino acids) by chromatography

  2,5-二酮哌嗪的双-内酯醚1包含一个手性诱导中心，一个酸性CH键和两个易于水解的位点。他们用BuLi反应以得到类型的锂化合物4，15，19或32，其具有前手性的C原子。他们很容易添加亲电试剂（例如烷基化剂或羰基化合物），具有非同寻常的非对映异构性。在许多情况下，加合物的减值（de =非对映异构体过量=不对称诱导）超过95％。水解时，加合物被裂解释放出手性助剂（用于构建双内酰胺醚1）和目标分子，即8型旋光氨基酸甲基酯，19，25或36。两种氨基酸酯可通过分馏或（最终在进一步水解成氨基酸后）通过色谱法分离。讨论了过渡状态模型，该模型可以解释异常高的不对称诱导和诱导构型的可预测性。
• Selective androgen receptor modulators
  申请人：Miller Chris P.

  公开号：US20090253758A1

  公开（公告）日：2009-10-08

  This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, and or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, Ie, and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds of formulas I, Ia, Ib, Ic, Id, Ie, and intermediates useful in the preparation of same.

  本发明提供了公式I、Ia、Ib、Ic、Id、Ie的化合物，以及它们的盐，包含这些化合物的药物组合物和药用辅料，调节雄激素受体方法，治疗可受益于雄激素受体调节剂（例如，肌肉减少症、前列腺癌、避孕、2型糖尿病相关疾病或病症、贫血、抑郁和肾脏疾病）的疾病的方法，以及制造公式I、Ia、Ib、Ic、Id、Ie的化合物和用于制备这些化合物的中间体的过程。
• Versuche zur Synthese des Peptidteils der Mutterkornalkaloide I. 27. Mitteilung über Mutterkornalkaloide
  作者：A. Stoll、Th. Petrzilka

  DOI：10.1002/hlca.19520350224

  日期：1952.2.1

  Es wird die Synthese von Dihydro-lysergyl-peptiden, welche D-oder L-Serin, bzw. D- oder L-Dimethylserin, L-Leucin und D- oder L-Prolin enthalten, beschrieben. In Modellversuchen wurden die entsprechenden p-Tosyl-peptide hergestellt.

  描述了包含D-或L-丝氨酸，或D-或L-二甲基丝氨酸，L-亮氨酸和D-或L-脯氨酸的二氢裂变能肽的合成。在模型实验中产生了相应的对甲苯磺酰基肽。
• Total synthesis of the large non-ribosomal peptide polytheonamide B
  作者：Masayuki Inoue、Naoki Shinohara、Shintaro Tanabe、Tomoaki Takahashi、Ken Okura、Hiroaki Itoh、Yuki Mizoguchi、Maiko Iida、Nayoung Lee、Shigeru Matsuoka

  DOI：10.1038/nchem.554

  日期：2010.4

  Polytheonamide B is by far the largest non-ribosomal peptide known at present, and displays extraordinary cytotoxicity (EC50 = 68 pg ml−1, mouse leukaemia P388 cells). Its 48 amino-acid residues include a variety of non-proteinogenic d- and l-amino acids, and the absolute stereochemistry of these amino acids alternate in sequence. These structural features induce the formation of a stable β-strand-type structure, giving rise to an overall tubular structure over 30 Å in length. In a biological setting, this fold is believed to transport cations across the lipid bilayer through a pore, thereby acting as an ion channel. Here, we report the first chemical construction of polytheonamide B. Our synthesis relies on the combination of four key stages: syntheses of non-proteinogenic amino acids, a solid-phase assembly of four fragments of polytheonamide B, silver-mediated connection of the fragments and, finally, global deprotection. The synthetic material now available will allow studies of the relationships between its conformational properties, channel functions and cytotoxicity. Polytheonamide B is a large non-ribosomal peptide with very high bioactivity. The synthesis described here includes the first preparation of several non-proteinogenic amino acids and a general coupling strategy for large non-natural peptides. The synthesis is a key step necessary to understand and utilize the bioactivity of this and similar compounds.

  聚糖酰胺 B 是目前已知的最大的非核糖体肽，具有非凡的细胞毒性（EC50 = 68 pg mlâ1, 小鼠白血病 P388 细胞）。它的 48 个氨基酸残基包括多种非蛋白原性 d 和 l 氨基酸，这些氨基酸的绝对立体化学结构依次交替。这些结构特征促使形成稳定的δ-strand 型结构，从而形成长度超过 30 Ã 的整体管状结构。在生物环境中，这种折叠结构被认为可以通过一个孔隙在脂质双分子层中运输阳离子，从而起到离子通道的作用。在此，我们首次报告了聚神酰胺 B 的化学结构。我们的合成依赖于四个关键阶段的结合：非蛋白源氨基酸的合成、聚草酰胺 B 四个片段的固相组装、银介导的片段连接以及最后的全局脱保护。现在可用的合成材料将有助于研究其构象特性、通道功能和细胞毒性之间的关系。聚神酰胺 B 是一种大型非核糖体多肽，具有极高的生物活性。本文描述的合成包括首次制备几种非蛋白源氨基酸和大型非天然肽的一般偶联策略。该合成是了解和利用该化合物及类似化合物生物活性的关键一步。
• The Synthesis, Resolution and Configuration of β-Hydroxyvaline
  作者：Jun-ichi Oh-hashi、Kaoru Harada

  DOI：10.1246/bcsj.39.2287

  日期：1966.10

  β-dimethylglycidate by aminolysis with benzylamine, followed by hydrogenolysis. N-Benzoyl-DL-β-hydroxyvaline was resolved by use of (−)-α-methylbenzylamine to yield (−)-N-benzoyl-β-hydroxyvaline. The configuration of VI was determined by converting it to methyl N-benzoyl-β-chlorovalinate (I) and subsequent hydrogenolysis of I yielded (−)methyl N-benzoylvalinate (II). From II, optically pure D-(−)-valine was

  DL-β-羟基缬氨酸是由β,β-二甲基缩水甘油酸钠通过苯甲胺氨解，然后氢解合成的。N-苯甲酰基-DL-β-羟基缬氨酸通过使用 (-)-α-甲基苄胺进行拆分，得到 (-)-N-苯甲酰基-β-羟基缬氨酸。VI 的构型通过将其转化为 N-苯甲酰基-β-氯缬氨酸甲酯 (I) 和随后的 I 氢解得到 (-) 甲基 N-苯甲酰基缬氨酸 (II) 来确定。从II，水解后获得光学纯的D-(-)-缬氨酸。